Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nanjing Legend Biotech Co. Ltd. currently has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners and 3 distinct art units. This suggests that while the company's focus is within biotechnology, its active applications are diverse enough to be reviewed by multiple specialized groups at the patent office. The concentration within 3 distinct art units indicates clustered research efforts.
GILL, RACHEL B is the busiest examiner for the portfolio, managing 1 pending office action. Because there are 5 distinct examiners for the 5 total actions, the workload is distributed across the patent office staff. This lack of concentration requires the company to manage 5 different examiner relationships while navigating the technical requirements of the 3 distinct art units involved in these pharmaceutical cases.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 3 (60%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILL, RACHEL B | 1 | 65.6% | +28.3% |
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
| MELCHIOR, JAMES RYLAND | 1 | 63.0% | +38.5% |
| BUTTICE, AUDREY L | 1 | 47.9% | +25.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026297 | T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF | BUTTICE, AUDREY L | 16d |
| 18849242 | METHODS FOR PREPARING DNA LIBRARIES AND DETECTING RETROVIRAL INTEGRATION SITES | GILL, RACHEL B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039420 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | MELCHIOR, JAMES RYLAND | 23d overdue |
| 18026297 | T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF | BUTTICE, AUDREY L | 16d |
| 18849242 | METHODS FOR PREPARING DNA LIBRARIES AND DETECTING RETROVIRAL INTEGRATION SITES | GILL, RACHEL B | — |
| 18286684 | CHIMERIC CYTOKINE RECEPTORS AND USES THEREOF IN CELLULAR THERAPIES | JUEDES, AMY E | — |
| 18276703 | ENGINEERED IMMUNE EFFECTOR CELLS EXPRESSING EXOGENOUSLY INTRODUCED CYTOKINES | SHUPE, ELIZABETH A | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1643 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18849242 | METHODS FOR PREPARING DNA LIBRARIES AND DETECTING RETROVIRAL INTEGRATION SITES | GILL, RACHEL B | — | §103§112 | Non-Final OA | — | Pending | Sep 20, 2024 |
| 18286684 | CHIMERIC CYTOKINE RECEPTORS AND USES THEREOF IN CELLULAR THERAPIES | JUEDES, AMY E | 1644 | §102§103§112DP | Non-Final OA | — | Pending | Oct 12, 2023 |
| 18276703 | ENGINEERED IMMUNE EFFECTOR CELLS EXPRESSING EXOGENOUSLY INTRODUCED CYTOKINES | SHUPE, ELIZABETH A | 1643 | §103DP | Final Rejection | — | Pending | Aug 10, 2023 |
| 18039420 | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA | MELCHIOR, JAMES RYLAND | 1644 | §103DP | Final Rejection | 23d overdue | Pending | May 30, 2023 |
| 18026297 | T CELL AND ANTIGEN-PRESENTING CELL ENGAGERS AND USES THEREOF | BUTTICE, AUDREY L | 1647 | §103§112 | Non-Final OA | 16d | Pending | Mar 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial